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ABSTRACT
Introduction: The objective of this study was to
provide an update on the resistance of
Escherichia coli in women with acute
uncomplicated urinary tract infections (UTIs)
in France, Germany, Spain, Sweden, and the
United Kingdom (UK) to mecillinam
[amdinocillin (United States Adopted Name)],
amoxicillin–clavulanic acid, cefadroxil,
nitrofurantoin, ciprofloxacin, and
trimethoprim, and to compare the results with
resistance in the ECO.SENS I and II surveys in
2000 and 2008, respectively.
Methods: The susceptibility of E. coli in France
(166 isolates), Germany (133 isolates), Spain
(169 isolates), Sweden (137 isolates), and the UK
(124 isolates) was determined by disc diffusion
according to European Committee on
Antimicrobial Susceptibility Testing (EUCAST)
breakpoints and methodology. Resistance rates
were compared using Fisher’s exact test,
2-tailed, with P\0.05 indicating statistical
significance.
Results: Since 2000, there has been a
significant increase in resistance to cefadroxil
in Germany (1% to 12%) and Spain (3% to 8%),
to ciprofloxacin in Germany (2% to 21%), Spain
(15% to 31%), Sweden (0% to 7%), and the UK
(1% to 15%), to trimethoprim in Germany (23%
to 37%), Spain (25% to 37%), Sweden (9% to
17%), and the UK (13% to 46%), to mecillinam
in Spain (1% to 6.5%), and to nitrofurantoin in
the UK (0% to 6%); there was also a significant
decrease in resistance to nitrofurantoin in Spain
(4% to 0%). Since 2008, there has been a
significant increase in resistance to
ciprofloxacin in Sweden (3% to 15%) and the
UK (1% to 15%), and to trimethoprim (13% to
46%) and nitrofurantoin (0% to 6%) in the UK.
Conclusion: E. coli isolates from women with
acute uncomplicated UTIs have increasing
antimicrobial resistance, particularly to
ciprofloxacin and trimethoprim. However,
resistance to mecillinam and nitrofurantoin
mostly remains low.
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INTRODUCTION
Antimicrobial resistance (AMR) in clinically
important pathogens, such as Escherichia coli,
is of continuing concern [1]. Changes in
resistance levels are best monitored by
prospective, multi-national, surveillance
programs, employing standardized procedures
to collect the isolates and determine their
antimicrobial susceptibility [2]. The ECO.SENS
(The pan-European Escherichia coli sensitivity
survey) project was the first such study to
investigate the antimicrobial susceptibility of
E. coli in acute uncomplicated urinary tract
infections (UTIs) in women. It was first
conducted between 1999 and 2000, involving
1417 isolates from 4734 women in 17 countries
[3], and again in 2008 involving 903 isolates
from 1697 women in 5 countries [4].
We report here an update on the
antimicrobial susceptibility of isolates of
similar origin from five countries which
participated in either both or one of the
previous surveys representing areas of Europe
with varying AMR problems.
METHODS
The selection of patients and procedures
involved has been reported previously and are
summarized only briefly here [3, 4].
Methodological differences if any are
described. The study involved isolates of E. coli
from non-hospitalized females aged 18 years
and over, with symptoms of acute
uncomplicated lower UTI, which included any
or all of the following: frequency, dysuria,
urgency, and suprapubic pain. In France (14
centers), Spain (3 centers), Sweden (1 center),
and the United Kingdom (UK; 2 centers), all
isolates were from patients in primary
healthcare. In Germany (four centers), isolates
were from women attending hospital clinics
and the laboratory had difficulties guaranteeing
the community origin of the isolates. Isolates
were sent to the Department of Clinical
Microbiology at the Central Hospital, Va¨xjo¨,
Sweden. Their antimicrobial susceptibility to
mecillinam [amdinocillin (United States
Adopted Name)], amoxicillin–clavulanic acid,
cefadroxil (as a screen for cephalosporin
resistance, particularly ESBL production),
nitrofurantoin, ciprofloxacin, and
trimethoprim was determined by disc diffusion
using the European Committee on
Antimicrobial Susceptibility Testing (EUCAST)
methodology and breakpoints [5, 6]. Isolates
resistant to the first-generation cephalosporin,
cefadroxil, were investigated for production of
extended-spectrum beta-lactamase (ESBL) by
double disc synergy testing using cefotaxime
with and without clavulanic acid and
ceftazidime with and without clavulanic acid.
Resistance rates were compared to those
obtained in 2000, for all countries and to
those obtained in 2008 for Sweden and the UK
for all antimicrobials with the exception of
amoxicillin–clavulanic acid. The methodology
for determining susceptibility to
amoxicillin–clavulanic acid in the current
study was different from that used in the
previous studies [7]. Statistical comparison was
by Fisher’s exact test, 2-tailed, with P\0.05
indicating statistical significance.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation at the
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respective institutions and with the Helsinki
Declaration of 1964, as revised in 2013. No
patient identifiers other than sex and age were
recorded and, as such, informed consent was
not required for inclusion in this study.
RESULTS
Percentage susceptibilities to the agents tested
are shown in Table 1. When compared to the
results from 2000, there were instances where
resistance had increased significantly in 2014,
as follows: Germany showed a significant
increase in resistance to cefadroxil (1.4% to
12.0%; P\0.001), ciprofloxacin (2.2% to
20.2%; P\0.0001), and trimethoprim (22.5%
to 36.8%; P\0.05); Spain showed a significant
increase in resistance to mecillinam (1.0% to
6.5%; P\0.01), cefadroxil (3.1% to 8.3%;
P\0.05), ciprofloxacin (14.7% to 30.8%;
P\0.001), and trimethoprim (25.1% to 37.3%;
P\0.05); Sweden showed a significant increase
in resistance to ciprofloxacin (0% to 7.3%;
P\0.001) and trimethoprim (8.8% to 16.9%;
P\0.05); and the UK showed a significant
increase in resistance to ciprofloxacin (0.6% to
15.3%; P\0.0001), trimethoprim (13.3% to
46.0%; P\0.0001), and nitrofurantoin (0% to
5.6%; P\0.01). Spain also showed a significant
decrease in resistance to nitrofurantoin (4.2% to
0%; P\0.01).
Resistance in 2014 was significantly greater
than that recorded in 2008 in the UK with a
significant increase in resistance to
ciprofloxacin (0.5% to 15.3%; P\0.0001),
nitrofurantoin (0% to 5.6%; P\0.01), and
trimethoprim (14.9% to 46.0%; P\0.0001).
Overall there were 35 (4.8%) isolates positive
for ESBL production. The incidence in each
country was 2.4% in France, 10.5% in Germany,
4.7% in Spain, 2.9% in Sweden, and 4.0%
in the UK.
DISCUSSION
E. coli from women with acute uncomplicated
UTIs in 2014 showed high levels of resistance to
ciprofloxacin, trimethoprim, and
amoxicillin–clavulanic acid. Significantly
greater resistance when compared to similar
isolates from both 2000 and 2008 was noted for
ciprofloxacin and trimethoprim. The current
study is particularly important in that it enables
trends in resistance to be compared over a
15-year period, as opposed to the usual surveys
which take only a snapshot at a specific time.
When compared to 2000, ciprofloxacin and
trimethoprim resistance had increased in
Germany, Spain, Sweden, and the UK.
Resistance had similarly increased to
ciprofloxacin and trimethoprim in the UK
since 2008.
There were only minor differences in
methodology between the first two surveys
and that reported here. The surveys in 2000
and 2008 involved many centers in each
country [3, 4]. In contrast, the latest study was
truly multi-center only in France, whereas
samples from the other countries came from
up to four centers. No upper age limit was
imposed on patients in the current study,
whereas an upper age limit of 65 years was
specified previously. Despite these differences,
the three surveys had very important
similarities. All involved women with acute
uncomplicated UTIs. Urine samples in all
three surveys were obtained from women in
primary healthcare, with the exception of
Germany in the current study, where most of
the isolates were from women attending
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hospital clinics. Antimicrobial susceptibility
was performed at the same laboratory for all
three studies.
Susceptibility in the current study was
determined using EUCAST breakpoints and
standardized methodology [5, 6]. The
methodology used in the current study was
different to that used previously, as it used a
different medium and inoculum as specified by
EUCAST. However, the zone diameter
breakpoints were the same for all
antimicrobials with the exception of
amoxicillin–clavulanic acid [5–7]. The most
recent guidelines for amoxicillin–clavulanic
acid use a fixed concentration of clavulanic
acid and apply specifically to urinary isolates [5,
6]. The new susceptibility breakpoint for isolates
from UTIs is defined as an amoxicillin
minimum inhibitory concentration of
B32 mg/L. Due to these differences in
methodology it is impossible and
inappropriate to compare the resistance rates
for this antimicrobial between on one hand
2014 and on the other 2000 and 2008. However,
it is acceptable to compare the results from the
three surveys for all other antimicrobials.
Statistical comparison is also acceptable,
although for the reasons discussed above, one
should not place too much emphasis upon the
degrees of statistical significance found.
Our results and the trends observed are
comparable to those observed elsewhere over a
similar timescale. In France, resistance to
amoxicillin–clavulanic acid [8] and
trimethoprim–sulfamethoxazole [8, 9] has
been highlighted, and there are similar reports
from Germany [10, 11], along with resistance to
cephalosporins [10]. Resistance to quinolones
and trimethoprim–sulfamethoxazole in Spain is
well documented [12, 13]. Although
antimicrobial susceptibility in E. coli isolates in
Sweden is generally high, trimethoprim
resistance levels have been a cause for concern
[14]. Similarly, the high level of trimethoprim
resistance in the UK is well documented [15].
The Antimicrobial Resistance
Epidemiological Survey on Cystitis (ARESC)
study in Europe and Brazil, which involved
similar patients to those in our study, noted
that susceptibility to E. coli of over 90% was
found for mecillinam, nitrofurantoin, and
fosfomycin only [16]. Although fosfomycin
was not tested in our latest study, consistent
and high susceptibility of E. coli in all countries
was similarly noted for mecillinam and
nitrofurantoin. Interestingly, investigation of
34 isolates of E. coli resistant to either
mecillinam or nitrofurantoin from the first
ECO.SENS study in 2000 indicated the low
probability of future clonal spread of resistance
to these agents [17]. Our update has confirmed
no major increase in mecillinam or
nitrofurantoin resistance has taken place in
the last 15 years.
ESBL production was recorded in 35 (4.8%)
isolates. This is greater than that recorded
previously in the 2008 ECO.SENS study (1.2%
of isolates), suggesting that the frequency of
ESBL-producing E. coli in the community is
increasing. The incidence was less than 5% in
all countries except Germany, where it was
10.5%, where isolates were from women
attending hospital clinics.
The continuing and increasing resistance to
ciprofloxacin and trimethoprim is disturbing
and impacts on the choice of therapy for
women with acute uncomplicated UTIs,
particularly in domiciliary practice, where
treatment is usually empirical. Antimicrobial
susceptibility surveys such as the ECO.SENS and
ARESC are essential and provide the most
appropriate information on which to base
such treatment. Our data, and that of others,
indicate that mecillinam, nitrofurantoin, and
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fosfomycin are suitable options for empirical
therapy of women with acute uncomplicated
UTI. These are old agents with indications
limited to lower uncomplicated UTIs. Interest
in the redevelopment of these old agents has
awakened with the galloping resistance to other
agents and with the lack of new agents [18].
CONCLUSIONS
E. coli isolates from women with acute
uncomplicated UTIs showed a significant
increase in AMR since 2000 to ciprofloxacin
and trimethoprim (Germany, Spain, Sweden,
and the UK). Susceptibility to mecillinam and
nitrofurantoin remains high. The ECO.SENS
and ARESC studies indicate that
suitable agents for empirical treatment of
acute cystitis include mecillinam,
nitrofurantoin, and fosfomycin.
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